Answers are grounded in this paper and cite their sources.
<.001). This analysis demonstrated a significant Q-TWiST gain for zanubrutinib versus ibrutinib in high-risk R/R CLL patients, providing valuable insights that may inform clinical decision-making.
No takes yet. Share an insight, caveat, or question.
Lévy et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: